Movement Disorders
Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
Subtype terms (11)
More specific conditions that are subtypes of Movement Disorders in the MeSH hierarchy.
- Akathisia, Drug-Induced
3 drugs (2 approved, 1 experimental)
- Angelman Syndrome
15 drugs (5 approved, 10 experimental)
- Dyskinesias
23 drugs (15 approved, 8 experimental)
- Dystonic Disorders
7 drugs (5 approved, 2 experimental)
- Essential Tremor
38 drugs (22 approved, 16 experimental)
- Hepatolenticular Degeneration
23 drugs (11 approved, 12 experimental)
- Multiple System Atrophy
65 drugs (36 approved, 29 experimental)
- Pantothenate Kinase-Associated Neurodegeneration
2 drugs (1 approved, 1 experimental)
- Parkinsonian Disorders
54 drugs (23 approved, 31 experimental)
- Supranuclear Palsy, Progressive
51 drugs (24 approved, 27 experimental)
- Tic Disorders
14 drugs (8 approved, 6 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (8)
Phase 2 trials (15)
Phase 1 trials (6)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (11)
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (5)